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ABSTRACT
Objective: Congenital myopathy as a nosologic entity has long been recognized, but knowledge of
overall and subtype prevalence and phenotype-genotype relationship is scarce, especially in the
adult population.
Methods: A national cohort of 107 patients $5 years diagnosed with congenital myopathy were
prospectively assessed clinically, histologically, and genetically.
Results: Twenty-five patients were excluded because of atypical features or alternative etiologies.
The remaining 82 were on average 28 years old. Histologic examination revealed 14 (17%) with
core disease, 15 (18%) centronuclear myopathy, 12 (15%) nemaline rods, 27 (33%) congenital
fiber-type disproportion or type I predominance, and 14 (17%) nonspecific myopathic changes.
Genetic etiology was identified in 46 patients (56.1%); 22.0% were heterozygous or compound
heterozygous for mutations in RYR1, 7.3% had DNM2 mutations, and 7.3% NEB mutations.
Less than 5% had mutations in ACTA1, TPM2/3, MTM1, TTN, SEPN1, or SC4NA. A genetic
cause was established in 83% with specific histology (cores/rods/centronuclear myopathy) vs
29% with unspecific histology. The detailed clinical examination found gene-dependent discrep-
ancies in the pattern of muscle affection and walking ability. Although walking ability was delayed
in patients withACTA1, TPM2/3, and RYR1mutations, it was within normal limits in patients with
NEB and DNM2 mutations.
Conclusions: We found that overall, genetic and histologic prevalence of congenital myopathy in
Denmark differs from previous retrospective reports. Less RYR1 and more DNM2 and NEB
mutations and less core histology were present in our cohort. These differences may be explained
by our prospective design, the older cohort of patients, and by differences in genetic background.
Neurol Genet 2017;3:e140; doi: 10.1212/NXG.0000000000000140
GLOSSARY
CCD 5 central core disease; CFTD 5 congenital fiber-type disproportion; CM 5 congenital myopathy; CMS 5 congenital
myasthenic syndrome; CNM 5 centronuclear myopathy; DNM2 5 dynamin 2; HGMD 5 Human Gene Mutation Database;
LGMD 5 limb-girdle muscular dystrophy; MRC 5 Medical Research Council; MTM1 5 myotubularin 1; NM 5 nemaline
myopathy; RYR1 5 ryanodine receptor 1; SEPN1 5 selenoprotein 1; WES 5 whole-exome sequencing.
Congenital myopathy (CM) has been recognized for decades, but the genetic cause is only es-
tablished in about half of cases1,2 and the knowledge of the distribution of genetic and histologic
subtypes is insufficient. Data concerning CM have been collected retrospectively and mainly in
pediatric patients.
The low genetic identification rate can partly be explained by undefined genes and by that
some of the genes associated with CM3–6 are very large, making analyses challenging. An
uncertain relationship between the genotype and the clinical/histologic phenotype also hampers
the identification of genetic etiology. CM is traditionally classified according to muscle histology
into nemaline, core, or centronuclear myopathies (CNMs). It has become increasingly clear,
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however, that not only can CMs be associated
with unspecific pathologies but the pathology
and genotype are not mutually specific.7 A
better understanding of prevalence and rela-
tionship between phenotypes and genotypes
is a prerequisite for patient care, corroboration
genetic findings, and ultimately development
of treatment. In Denmark, patients with CM
are registered at 2 centers. We made use of this
opportunity to prospectively evaluate pheno-
types and genotypes in a national cohort with
a diagnosis of CM.
METHODS The study was conducted at the Copenhagen
Neuromuscular Center, Rigshospitalet, Denmark, in collabora-
tion with the Danish National Rehabilitation Centre for Neuro-
muscular Diseases. One hundred nineteen patients registered
with a diagnosis of CM aged older than 5 years were invited.
Two patients were not invited because of severe psychiatric co-
morbidity. The age limit of 5 years was chosen, as the functional
tests used were not validated for younger patients and because we
wanted to focus on older CMs. All participants completed ques-
tionnaires concerning symptoms and medical history. A neurolo-
gist (N.W.) and a physiotherapist (U.W.) examined all patients.
Muscle strength was evaluated using a transformed 11-point
Medical Research Council (MRC) scale (0–10).8 Creatine
kinase was assessed and DNA was isolated. After initial
evaluation, participants with phenotypic characteristics atypical
for CM (adult onset, fast progression, creatine kinase$600 U/L,
dystrophy as the main histologic finding, or alternative disease
explanation) were excluded. Participants with a CM phenotype,
but other genetic etiology, were excluded in the course of the
genetic evaluation.
Standard protocol approvals, registrations, and patient
consents. The study was approved by the local ethics committee
(protocol H-C-2009-017), and all participants or their parents
provided informed consent.
Genetic test strategy. All participants were tested sequen-
tially for mutations in skeletal muscle alpha actin 1 (ACTA1)
and tropomyosin 213 (TPM213) genes, as no definite his-
tologic or clinical phenotypes are established for these genes,
and the tests were readily available. Second-line analyses were
directed by specific histologic or phenotypic findings. Core
histology (central core disease [CCD]) elicited testing of the
ryanodine receptor 1 (RYR1) gene and the selenoprotein 1
(SEPN1) gene. CNM or pronounced ophthalmoplegia leads
to assessment of the genes dynamin 2 (DNM2), myotubularin
1 (MTM1), amphiphysin (BIN1), and RYR1. Rigid spine
patients went through SEPN1 testing. Pronounced
contractures led to the investigation of collagen VI genes
(not considered CM by the authors). The remaining
unclassified patients were examined for aberrations in NEB
and RYR1, and if no mutations were found, exome
sequencing was performed in the majority (Broad Institute,
Boston or Nijmegen University, Holland) with subsequent
assessment of genes involved in myopathy.
Genetic analyses. DNA was isolated from blood. The exons
and flanking sequences of ACTA (NM_001100.3), TPM2
(NM_003289.3), and TPM3 (NM_152263.2) were PCR
amplified and Sanger sequenced using BigDye v1.1 on an
ABI3130 sequencer. Analysis of DNM2 is described elsewhere.7
The NEB (NM_004543.4) and RYR1 (NM_000540.2) genes
were sequenced using a custom AmpliSeq targeting approach
on an Ion PGM (Thermo Fisher). Areas with low (,30X) or
missing coverage were Sanger sequenced. Data analysis was per-
formed on the Torrent Suite v.3.6 or higher. All variants were
confirmed by Sanger sequencing.
RESULTS Participants. One hundred seven of the
119 invited participants were included (figure 1).
Twenty-five were excluded, leaving a total of 82 in
the study. Of the excluded, 14 displayed a phenotype
inconsistent with CM; 3 of these were subsequently
confirmed with limb-girdle muscular dystrophy, type
1C (LGMD1C), LGMD2L, and LGMD2A. Eleven
had a phenotype compatible with CM, but an
alternative genetic etiology was identified in 10, and
DNA was missing in 1 (figure 1).
Prevalence and distribution of histology. Denmark has
5.4 million inhabitants older than 5 years. With 82
CM cases, prevalence is estimated to 2:100,000 in
persons older than 5 years.
Forty-one had specific histology; 14 (17%) had
cores (3 multimini core disease), 15 (18%) had
CNM, and 12 (15%) nemaline myopathy (NM).
The remaining 41 had more unspecific histology;
27 (33%) had congenital fiber-type disproportion
(CFTD) or type I predominance (T1), and 14
(17%) had unspecific myopathic biopsies. In 2,
biopsy material was unavailable (table 1).
Genetics. A genetic diagnosis was reached in 46
(56.1%) (tables 1 and 2). Eighteen had mutations
in RYR1 (22.0%) (13 heterozygous and 5 compound
heterozygous), 6 had mutations in DNM2, and 6 in
NEB. Three or less had mutations in ACTA1, TPM2,
TPM 3, MTM1, SEPN1, SCN4A, or TTN genes
(tables 1 and 3). Twenty-one participants had
a particular clinical/histologic phenotype leading to
a genetic diagnosis. Twenty-five patients had no
clinical or histologic clues, and genetic etiology was
identified by single gene testing in 20 and by whole-
exome sequencing (WES) in 5; 3 with recessive RYR1
mutations, 1 with mutation in TTN, and 1 with
mutation in SCN4A.
The diagnostic yield was highly dependent on his-
tologic findings (table 2); if only participants with
cores, CNM, or NM were evaluated, a genetic etiol-
ogy was identified in 83%. If CFTD/T1 were
included, the number decreased to 63%.
A genetic etiology was identified in 3/14 (21%)
with unspecific histology, 9/27 (33%) with CFTD/
T1, 12/12 (100%) with NM, 9/14 (64%) with cores,
and 13/15 (87%) of participants with CNM. CFTD
and T1 were pooled, as these histologies coexisted in
the same families.
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The 10 participants with a phenotype compati-
ble with CM, but alternative genetic etiology had
collagen myopathy, desminopathy, or congenital
myasthenic syndrome (CMS) (figure 1). Seven of
10 had unspecific or CFTD histology, whereas the
remaining 3 had more specific histology: one with
desminopathy had cores, another with desminop-
athy had rods, and one collagen VI had centronu-
clear changes (table 2).
The age of genetically unresolved (27.86 16.7) and
resolved (28.0 6 14.6) patients was identical. The
genetically unresolved had generally more unspecific
histology and were less severely affected (tables 2 and 3).
Mutations. A total of 48 different mutations were
identified of which 31 were listed in the Human
Gene Mutation Database (HGMD) or ClinVar as
pathogenic. The remaining 17 were absent from the
Figure 1 Patient flow
ACTA1 5 skeletal muscle a-actin 1; AD 5 autosomal dominant; AR 5 autosomal recessive; CK 5 creatine kinase; CMS 5
congenital myasthenic syndrome; DES 5 desmin; DNM2 5 dynamin 2; DOK7 5 downstream-of-kinase 7 myasthenic
syndrome; LGMD5 limb-girdle muscular dystrophy;MTM15myotubularin 1;NEB5 nebulin; RAPSN5 receptor-associated
protein of the synapse myasthenic syndrome; RYR1 5 ryanodine receptor 1; SCN4A 5 sodium channel 4A; SEPN1 5
selenoprotein 1; TPM2/3 5 tropomyosin 2/3; TTN 5 titin. *Of these 6, 1 had LGMD2L, 1 LGMD2A, and 1 LGMD1C.
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HGMD or ClinVar and to our knowledge have not
been associated with disease before. Twelve of these
were identified in recessively inherited disorder; 8
were predicted to result in premature stop codons
or frameshifts and 4 were missense mutations. The
4 missense mutations were identified in SEPN1,
RYR1, and SCN4A, respectively, where mutations
very often are missense and were predicted to be
potentially pathogenic by SIFT, PolyPhen2, Align-
GVGD, and MutationTaster in silico prediction
softwares and were absent from the ExAC database
compiling information of more than 120,000 alleles
(exac.broadinstitute.org), and from a Danish control
cohort of 2000 WES.9 Of the 4 variants, 2 were
identified along with a known pathogenic mutation,
whereas the remaining 2 were identified in SEPN1
in a patient with a clear clinical presentation of
a selenoprotein deficiency. Where family members
were available, segregation analyses were performed
to conform a compound heterozygous state.
The remaining 5 novel variants were all missense
variants in RYR1 located in the well-known hot-
spot region for the dominantly inherited RYR1
disorder.10
Phenotypes. From the detailed muscle examination,
some patterns of weakness could be recognized
for particular genotypes (table 3, figure 2). The AC-
TA1 patients were generally very weak in proximal,
distal, and respiratory muscles, although 1 adult
patient did not follow this pattern. By contrast, the
TPM2/3 patients had few MRCmeasurements below
7, but despite this had the same decrease in respira-
tory function as the ACTA1 patients. NEB patients
typically had preferential affection of the shoulder
girdle and pronounced ankle dorsiflexor weakness
with MRC of just 1–2, but comparatively mild respi-
ratory involvement. As expected, dominant and reces-
sive RYR1 patients differed in severity, with recessive
patients being more severely affected. The DNM2
patients had a relatively nonselective profile except
a marked ankle weakness. The MTM1 patients were
more severely affected than the others, but hand func-
tion was relatively better than that in the ACTA1
patients. The respiratory involvement in the MTM1
and SEPN1 patients exceeded that in all other groups.
Finally, scoliosis was noted in the SEPN1 patients,
but otherwise only occasionally. Contractures were
not prevalent, but were noted in some NEB, RYR1,
DNM2,MTM1, TTN, and SEPN1 patients (table 3).
Ophthalmoplegia was confined to DNM2 and
MTM1 and recessive RYR1. Ptosis was mostly seen
in DNM2 patients. Average time of walking ability
was calculated in groups with more than 3 patients
and exceeded the World Health Organization–
defined normal limit of 18 months in patients with
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mutations in ACTA1 (30 months), TPM2/3 (20
months), and RYR1 (21 months, 2 never walked),
whereas patients with mutations in NEB (15 months)
and DNM2 (14 months) fell within normal devel-
opment. Four patients (a genetically unresolved par-
ticipant aged 26 years, 1 DNM2 patient aged 69, an
RYR1 patient aged 55 years, and a TTN patients aged
13 years) died during the study period from 2009
until now.
Information on work history was available in 42 of
the 46 genetically verified cases; 36 attended school or
worked part or full time. The remaining 6 received
pension. No participant had clinical evidence of car-
diac involvement, and ECG performed in nearly all
participants was unremarkable.
DISCUSSION The present study investigated pa-
tients with CM older than 5 years. As only survivors
from the early childhood were included, the infor-
mation gathered is helpful for health care personal
caring for older children and adults because existing
knowledge has been obtained preferentially from
pediatric cohorts. The study is also a prospective,
national study of phenotypes and genotypes in
CM. Therefore, unlike previous retrospective stud-
ies, the study is less affected by selection bias and
strengthened by a systematic data collection by just
1 neurologist and physiotherapist. The report
presents new data on national prevalence,
distribution of histologic subtypes and genotypes,
and expands the description of phenotypic charac-
teristics. Because of the relatively low number of
participants, the data need confirmation.
We estimated a prevalence of 2:100,000. This is
lower than most previous studies, which determined
the prevalence by chart reviews or databases to about
4:100,000 and focused on the pediatric population.11–13
The exclusion of children not surviving to 5 years in our
study could account for some of the discrepancy. A
previous study reported that 12% of their patients with
CM died before the age of 6 years. Those patients had
mutations in ACTA1, MTM1, or KLHL40.2 Patients
with mutations in those genes may therefore be under-
represented in our material if extrapolated to a general
population. The total prevalence, however, is probably
not much influenced by this, as we, compared to pre-
vious studies, have included more elderly persons and
in that way “compensate” for the lack of young chil-
dren. Another explanation for our lower prevalence
estimate could be that the prospective evaluation in
our study may have eliminated more wrongly diag-
nosed patients. This is, however, probably not the main
explanation for the discrepancy, as most of the studies
were very thorough in the attempt to avoid misdiagno-
sis.11–13 Alternatively, our very stringent inclusion crite-
ria may have omitted a few CMs with atypical features
like high creatine kinase. Of the 15 excluded cases
because of atypical features, however, 10 had definitely
not CM, as alternative etiologies were identified or they
turned out to be asymptomatic family members.
Citizens in Denmark are easily traceable, as they
are centrally registered, and therefore, the lower prev-
alence in our study is not likely caused by problems in
identifying patients. A number of inherited muscle
diseases, such as some limb-girdle muscular dystro-
phies14 and myotonic dystrophy type 2, differ mark-
edly in prevalence in Denmark vs other countries, and
this could also be the case for CMs. In support of this,
CM has the same low prevalence in Northern Eng-
land (1.37:100,000, including Bethlem myopathy
Table 2 Chance of identifying genetic etiology according to histology
Proportion of gene identification
Proportion of
histology CM gene
Non–CM
gene
GenesN % N % N %
Unspecific histology
(CFTD/T1/myopathy/fibrosis)
49 12 25 7 15
Specific histology (ex CFTD) 44 34 77 3 7
NM 13 14 12 92 1 8 DES
Cores 15 16 9 60 1 7 DES
CNM 16 17 13 81 1 6 ColVI
CFTD/T1 32 35 9 28 5 16 2 ColVI, 3 ColXII
Myopathy/fibrosis/NO 16 17 3 19 2 13 1 DOK7, 1 RAPS
Sum/% 92 100
Abbreviations: CFTD 5 congenital fiber-type disproportion; CM 5 congenital myopathy; CNM 5 centronuclear myopathy;
NM 5 nemaline myopathy; NO 5 no report; TI 5 type I dominance.
CM phenotype with noncongenital genetic etiology was included.
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Table 3 Characteristics of patients with or without genetic diagnosis
ID/sex/age at examination, y Gene/mutation
Protein
consequence Histology Course
Walk,
mo old
Ophthalmoplegia/
ptoses
Face/voice/palate/facial
palsy/neck Limbs
FVC %
exp
Contractures/
scoliosis/other Occupation
Genetically diagnosed
patients
ACTA1 NM_001100.3
16/M/23 c.16 G.A p.Glu6Lys CFTD / 24 N/N Oblong/NV/H/F/StW, NK6 UL 7P, 9D, LL
7P 5 D
47 MD
42/M/12 c.128A.G p.Gln43Arg TI / 42 N/N Dysarthria, short frenulum/
H/F111/NK4
UL 3P, 7D, LL 2P,
6D
90 Student
44/M/15 c.142G.A p.Gly48Ser CFTD [ 30 N/N H/F/NK6 UL 5P, 9D, LL 6P,
9D
55 Student
49/F/10 c.1106C.T p.Pro369Leu TI/NM / 24 N/N H/NK6/dysphagia, tired
chewing
UL 4P, 6D, LL 5P,
9D
53 School
TPM2 NM_003289.3 p.Glu6Lys
34/F/14 c.415_417delGAG p.Glu139del NA / 23 N/Y Oblong/H/F/NK7/tired
chewing
UL 5P, 9D, LL 5P,
8D
58 S Student
35/F/39 34 daughter p.Glu139del NM/
CFTD
/ 15 N/Y(Su) Oblong/H/FNK6/tired
chewing
UL 6P, 9D, LL
8P 5 D
74 Pes cavus NI
TPM3 NM_152263.2
5/M/27 c.503G.A p.Arg168His CFTD / 17 N/N Triangular/NV/H11/NK7 UL 8P, 10D, LL
10P, 9D
46 (C)/(S) IT expert
91/M/19 c.502C.T p.Arg168Cys CFTD [ 24 N/N Oblong/NV, dysarthria/H/
NK6, malocclusion
UL 7P, 9D, LL 8P,
7D
57BiPAP RN Student
NEB NM_004543.4
7/F/29 c.2836-2A.Ga;
c.576315G.A
p.?; p.? NM Y 22 N/N H/F/NK7/dysphagia UL 5P, 8D, LL 4P,
6D
77 /S/Rec patella lux
(Su)
Part-time job
18/M/27 Brother to 53 NM / 15 N/N Oblong/F/NK10 UL 7P, 9D, LL 8P,
9D
72 Economist
53/M/24 c.241511G.A;
c.241511G.A
p.?; p.? ND / 12 N/N H/F/NK10 UL 6P, 8D, LL
9P 5 D
83 Hyperlax FE Shop ass
47/F/26 c.10354T.C;
c.17725G.T
p.Tyr3452His; p.
Glu5909*
NA Y 14 N/N Retrognathia(Su)/NV/H/F//
NK5/dysphagia
UL 7P, 10D, LL
7P, 3D
83 A(Su)//Rec K lux(Su) Pensioner
48/F/7 c.11330dupa;
c.10354T.C
p.?; p.Tyr3452His NM / 12 N/N H/F/NK7 UL 6P, 6D, LL 7P,
4D
86 School
58/M/49 c.12130C.T;
c.17503_17505dela
p.Arg4044*; p.
Asp5835del
NA Late N/N H/NK9 UL 8P, 7D, LL
10P, 5D
79 E, FF/ Full-time work
RYR1AD NM_000540.2
6/F/36 c.14818G.C p.Ala4940Thr CC/NM / 18 N/N Oblong/NV/H/NK5 UL 8P 5 D, LL
7P, 8D
62 A/S(Su) Office
24/M/22 c.14582G.A p.Arg4861His CC? / Never N/N H/(F)/NK5 UL 5P, 7D, LL 2P,
6D
62 K, HF(Su)/S(Su) Pensioner
Continued
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Table 3 Continued
ID/sex/age at examination, y Gene/mutation
Protein
consequence Histology Course
Walk,
mo old
Ophthalmoplegia/
ptoses
Face/voice/palate/facial
palsy/neck Limbs
FVC %
exp
Contractures/
scoliosis/other Occupation
25/F/38 c.14567C.G p.Ala4856Gly CC / 14 N/N (H)/NK9 UL 7P, 10D, LL
7P, 9D
90 Part-time
draftsman
31/F/27 c.14422-
14423delinsAAa
p.Phe4808Asn CC / Never N/N NV/H/(F)/NK7 UL 5P, 8D, LL 3P,
8D
90 Hip lux Pensioner
33/F/14 c.7523G.A p.Arg2508His T1 / 28 N/Y Oblong//NV, dysarthria/H/
F/NK8 tired chewing
UL/P, 10D, LL 7P,
10D
A/S/hyperlax School
61/M/62 c.13913G.A p.Gly4638Asp CC / 24 (Y)/Y NV/H/F/NK9 UL 6P, 10D, LL
7P, 8D
94 Medical doctor
64/F/27 Daughter of 61 CC / 24 N/N NV/H/NK10 UL 7P, 10D, LL
8P, 9D
NA A/hyperlordotic Sales assistant
83/M/63 c.14567C.Ta p.Ala4856Val / 15 N/N (F)/NK10 UL 8P, 10D, LL
8P 5 D
97 Chauffeur
84/M/19 Son of 83 NA [ 20 N/N H/F)/NK10 Normal 100 Electrician
trainee
62/M/18 c.14567C.Ta p.Ala4856Val [ 18 N/N NV/H/F/NK10 Normal 75 Student
89/M/31 c.14929G.Aa p.Glu4977Lys M / 12 N/N Oblong/H/F/NK10 UL 9P 5 D, LL
10P 5 D
77 Cong hip lux Gardener, sick
leave
94/M/22 c.13891T.Ca p.Tyr4631His CC/NM/
CFTD
/ 32 N/N NV/H/NK9 UL 5P, 7D, LL 6P,
8D
82 A/S/hyperlax E1Fi Full-time office
job
105/F/28 c.479A.G p.Gly159Glu CC / 24 N/N Oblong/NV/H/(F)/StW/NK6 UL 8P, 9D, LL 6P,
9D
NA A, Aa(Su)//RS,
hyperlax Fi
Psychologist
RYR1AR NM_000540.2
2/M/50 c.2427_2446dupa;
c.325C.T
p.Pro816Hisfs*75;
p.Arg109Trp
CN/D / 36 Y/N NV/H111/F/NK6 UL 4P, 8D, LL 4P,
10D
68 Full-time work
9/M/10 c.325C.T;
c.2989C.T
p.Arg109Trp; p.
Arg997*
CFTD / 15 Y/Y Triangular//H/(F)/NK3, tired
chewing
UL 4P, 7D, LL 3P,
9D
45 School
70/M/22 c.718C.T;
c.2897C.Ta
p.Gln240*; p.
Pro966Leu
CFTD [ 16 Y/Y H/F/tired chewing,
dysphagia, NK9
UL 6P, 10D, LL
5P, 9D
74 A, HF//rec hip1 Sh
lux
NI
81/F/28 Sister to 107 ND / 15 N/N F/NK3 UL 3P, 9D, LL 2P,
8D
72 Social worker
107/F/33 c.325C.T;
c.7308_7309delTGa
p.Arg109Trp; p.? CN / 24 Y/N NV/H/F/NK2/tired chewing,
dysphagia
UL 2P, 6D, LL 2P,
8D
NA Wheelchair Part-time social
worker
DNM2 NM_004945.3 p.?
8/M/25 c.1393C.T p.Arg465Trp CN / 18 (Y)/Y Oblong/F/NK7 UL 8P, 10D, LL
10P, 9D
74 Part-time
student
46/M/19 c.1840G.A p.Ala614Thr CN Y 17 Y/Y Skewed cranium/NV,
dysarthria/H/F/NK3
UL 2P, 5D, LL 2P,
5D
19 RN Pensioner
50/F/69 c.1393C.T p.Arg465Trp CN / (Y)/Y F/NK6 UL 5P, 6D, LL 5P,
1D
81 Retired (died)
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Table 3 Continued
ID/sex/age at examination, y Gene/mutation
Protein
consequence Histology Course
Walk,
mo old
Ophthalmoplegia/
ptoses
Face/voice/palate/facial
palsy/neck Limbs
FVC %
exp
Contractures/
scoliosis/other Occupation
82/F/41 c.1393C.T p.Arg465Trp CN / 9 N/N H/F/NK8 UL 7P, 8D, LL 7P,
4D
68 Part-time
teacher
67/F/20 c.1102G.A p.Glu368Lys CN / 14 (Y)/(Y) Oblong//H/(F)/N/NK6 UL 6P, 7D, LL 7P,
5D
56 A(Su), FF//RN Part-time
student
85/F/52 c.1553G.A p.Arg518His CN/CFTD / 12 Y/N Oblong/NV/H/NK5 UL 9P, 8D, LL 8P,
5D
88 Health care
worker
MTM1 NM_000252.2
37/M/14 c.135311G.A p.? CN / N Y/Y Oblong/NV/H/F/NK2 UL 2P, 5D, LL 2P,
3D
IV /S(Su) Special terms
stud
80/M/18 c.674T.C p.Ile225Thr CN / 36 Y/N F/NK2 UL 2P, 6D, LL 1P,
3D
19 A(Su)//wheelchair Special terms
stud
102/M/24 c.1037 G.C p.Trp346Ser CN/CFTD [ 18 Y/N Oblong/NV/H/(F)/NK4 UL 4P, 9D, LL 4P,
8D
25 Pes cavus/clawfoot Student
SEPN1 NM_020451.2 Er
17/F/34 c.802C.T;
c.1574T.G
p.Arg268Cys; p.
Met525Arg
NM/D / 12 N/N NV/H/F/StW, NK0 UL 7P, 8D, LL
P 5 D 5 8
IV (C)/S(Su) Part-time job
101/F/20 c.893T.C;
c.1396C.Ta
p.Leu298Pro; p.
Arg466Trp
NA Y N/(Y) Triangular/NV/H/(F)/StW/
NK2
UL 7P, 10D, LL
4P, 9D
22 /S(Su) Pensioner
103/F/27 c.*1107T.C;
c.943G.A
p.?; p.Gly315Ser MCD Y 12 N/N NV/H/(F)/StW, NK4 UL 6P, 10P, LL
4P, 9D
30BiPAP A, RN/S Pensioner
TTN NM_133378.4 p.?; p
14/M/13 c.16745C.G;
c.97719C.Ga
p.Ser5582*; p.
Tyr32573*
CN Y Never N/N Retrognathia/NV/H11/(F)/
NK3
UL 3P, 6D, LL 2P,
4D
NIV Hand K(Su)/S(Su) Dead
SCN4A NM_000334.4 P
52/F/30 c.673C.T;
c.3626G.Ta
p.Arg225Trp; p.
Cys1209Phe
M / 18 Y/N Oblong/NV/H/F/StW, NK5 UL 7P, 10D, LL
6P, 0D
82 Hyperlordosis Laboratory
tech part time
Characteristics of not
genetically diagnosed
patients
1/M/66 NA NA CC, NM,
Dy
Y NA N NV/H111/StW, NK3 UL 6P, 9D, LL 5P,
3D
70 Oromandibular, FE,
A//pes cavus
Pensioner
54/M/69 NA NA CC / NA N (F)/NK10 UL 8P, 9D, LL
7P 5 D
64 Oromandibular, Sh,
K, A, wrists
Pensioner
3/F/18b NA NA M / 20 N NV/NK10 10 75 Student
4/M/13 NA NA T1 / 20 N NV/NK9 UL 9P, 10D, LL
9P 5 D
75 School
10/M/35b NA NA MCD Y NA Y/N Oblong/NV/F/NK2 UL 2P, 7D, LL 2P,
3D
IV (All joints)/S(Su)/
wheelchair
Pensioner
12/F/59b NA NA M Y NA N /NK8 UL 6P, 7D, LL
4P 5 D
100 A(Su), plantarflex/ Secretary PT
Continued
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Table 3 Continued
ID/sex/age at examination, y Gene/mutation
Protein
consequence Histology Course
Walk,
mo old
Ophthalmoplegia/
ptoses
Face/voice/palate/facial
palsy/neck Limbs
FVC %
exp
Contractures/
scoliosis/other Occupation
95/F/32 NA NA Normal / 10 N /NK10 UL 9P, 10D, LL
9P 5 D
100 NI
56/M/32 NA NA M / NA N /NK9 UL 5 LL 9P, 10P NA A, Fi, K//hyperlax Draftsman
15/F/18c NA NA CFTD / 16 N/Y NV/H/NK10 Normal 100 /S School
19/M/22b NA NA MCD / Never N/N Oblong/H/NK3 UL 2P, 6D, LL 2P,
5D
35 K, E, Fi, hip(Su), A,
Aa/S(Su)
Student
20/M/14b NA NA T1 / 20 N/Y Oval, retrognathia/NV/H/
NK10
UL 9P, 10P, LL
10P 5 D
100 School
22/F/28b,c NA NA T1 / 16 (Y)/Y H/F/NK9 UL 6P, 10D, LL
6P, 9D
73 Dietician PT
28/F/55b NA NA NA / NA N (H)/NK8 UL 5 LL 8P, 10 100 /(S) Physiotherapist
39/M/40 NA NA CFTD / NA N StW, NK10 UL 8P, 10D, LL
9P, 10D
84 NI
51/F/35 NA NA CFTD / NA N NK6 Asym, UL P4, 9D,
LL P7, D10
82 KF, HF(Su), RN/S/
hyperlax
Psychologist
PT
72/F/38 NA NA NA / 14 N (H)/StW, NK8 10 92 FF//rec patella lux Teacher PT
71/F/11 NA NA M / 13, AM N (H)/StW, NK5/tired chewing UL 5P, 10D, LL
7P, 6D
52 KF, HF, EF, A(Su),
thumb/S
Special school
29/F/41 NA NA M Y NA N Oblong/NV/H/StW, NK9 UL 9P, 10D, LL
9P, 5D
90 A Graphic
designer
32/F/21b NA NA CCD [ NA N Oblong/NV/H/F/NK6 UL 5P, 8D, LL 4P,
8P
82 Student
41/M/21b NA NA M Y NA N/Y H/NK10 UL 9P 5 D, LL
8P, 9D
94 A Student
55/F/17b NA NA CFTD / NA N/Y NV/H/F/NK8 UL 6P, 9D, LL 8P,
8D
53 FF, HF, KE, RN, A/S Student
59/M/44b NA NA CNM / 24 N (H/F)/NK4 UL 5P, 9D, LL 3P,
5D
72 A, hyperlax Jeweler
63/F/14 NA NA Normal / NA N/Y NV/H/F NA 60 Special school
65/M/26b NA NA M / 24 N Oblong/NV/(H)/NK10 UL 9P, 10D, LL
9P, 10D
89 Sh NI
66/F/11c NA NA M / 34 N (H)/NK9 UL 7P, 5D, LL 8P,
6D
NA //Rec lux; K, A, Sh Special school
68/M/8b NA NA M [ 23 N F/NK9, tired chewing UL 8P 5 D, LL 9P
5 D
78 School
74/M/13b NA NA CFTD / 17 Y/Y H/F/NK10 UL 8P, 9D, LL 0P,
8D
91 /S/hyperlax School
75/F/25b NA NA NA [ NA N NV/F/NK10 UL 8P, 10D, LL
10P 5 D
65 Childcare PT
Continued
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with a prevalence of 0.77) as in Denmark, where the
genetic influence from historic Viking invasions is
great.15
A London-based study1 observed a different pat-
tern of histology, as the majority of their patients
had CCD, whereas histologic findings of cores,
CNM, NM, and CFTD/T1 were more evenly dis-
tributed among our patients. This difference in his-
tology also points to a different genetic background
and supports that not only the prevalence but also
the genetic make-up of CM varies among geo-
graphic regions. Concurring with this hypothesis,
the genetic etiology in the London-based study
was very different from ours. They found RYR1
mutations in 59% and DNM2 in 0% of their
CMs, whereas RYR1 mutations were observed in
22% of our cases and DNM2 mutation in 7.3%.
The difference in RYR1 mutations in our popula-
tion is probably not explained by different age dis-
tribution, as RYR1 patients usually survive past
early childhood.2 The DNM2 patients, however,
are relatively mildly affected and may go unrecog-
nized for years, which would make them underrep-
resented in a very young population. We also found
a higher percentage of patients with NEB mutations
in our cohort. This discrepancy, however, could
relate to differences in testing strategies, where we
sequenced all nonrepetitive coding sequences of
NEB, whereas only a single frequent deletion was
assessed in the previous study.1 Also, the genetic
background may influence the distribution of
genetic etiology.
We identified the genetic etiology in 56% of pa-
tients. Two recent studies (same group) describing
retrospective data in mostly pediatric patients re-
ported the genetic cause in 67%–79%.1,2 Our lower
diagnostic rate can partly be explained by methods
of selecting patients, as we included many patients
with unspecific myopathic biopsies and that sub-
group only had a genetic etiology identified in
21% of cases. Leaving the patients with unspecific
myopathic histology out, we found a genetic etiol-
ogy in 63% if CFTD/T1 was included, and 83%
without CFTD/T1. Differences in the success rate
of identifying genetic etiology are therefore most
likely caused by differences in histology among
the included cohorts. An alternative explanation
might be that our patients were older than those
in previous studies and that those who die before
age 5 years often have mutations in ACTA1 or
MTM1,2 which are relatively easy to identify.
Finally, the genetic background may vary as dis-
cussed above.
The chance of identifying genetic etiology was
highly dependent on histology. A much higher per-
centage with a “specific” histology like cores, NM,
T
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or CNM had a genetic etiology identified. In the
subgroup with confirmed CM and NM, genetic eti-
ology was identified in 100%. However, the specific-
ity of CM is not 100%, as 1 patient with desmin
mutation also had NM. NM in patients with desmin
mutations has only been reported in a few cases,16 but
was attributed to the known protein accumulation in
desminopathy. “Specific histology” for CM, however,
was only found in 3/10 patients with a phenotype
compatible with CM, but with alternative genetic
diagnoses (CMS, desminopathy, ColVI, or XII). A
patient with selenoprotein deficiency had nemaline
bodies in 2 muscle fibers. Although this might be
an incidental finding, this patient was grouped
together with the NMs.
The detailed physical examination performed in
this study suggests some new clinical clues to the
genetic etiology. In the genetically resolved nema-
line/CFTD/T1 group, ACTA1 patients were gener-
ally weaker than NEB patients.17 However, in
contrast to the NEB patients, patients affected by
TPM2 and 3 aberrations had a disproportionately
higher respiratory affection, and half of the NEB pa-
tients had almost paralytic ankle dorsiflexion coexist-
ing with MRC 7–8 in proximal muscles and
a relatively preserved hand function. The preferential
weakness of ankle dorsiflexors in some NEB patients
is well established.18,19 The only patient with com-
bined CFTD and pronounced ophthalmoplegia had
recessive RYR1 disease. The recessive RYR1 patients
also exhibited a marked proximal-distal gradient in
weakness, which was shared by the MTM1 patients,
but the MTM1 patients had a much more noticeable
respiratory affection. Severe ophthalmoplegia was, in
agreement with a recent consensus statement,19 exclu-
sively observed with recessive RYR1, DNM2, and
MTM1 mutations. CCD was almost synonymous
with dominant RYR1 mutations, and these patients
had much the same extremity affection as SEPN1
patients, and both groups had a tendency to scoliosis.
The SEPN1 patients, however, had much more respi-
ratory and axial involvement as known for this con-
dition. Mutations in DNM2 lead to CNM with
ptosis and a lower extremity distal affection in all
cases, but otherwise a relatively mild phenotype.
Although these clinical clues are not 100% consistent,
we believe that they contribute importantly when
planning a genetic test strategy or interpreting test
results.
Ten patients were initially judged to have a phe-
notype compatible with CM, but turned out to
have mutation in a gene not strictly belonging to
the genes recognized as genes inducing CM; 3
had mutations in the collagen VI gene, 3 in the col-
lagen XII gene, 2 in the desmin gene, and 2 had
CMS. The delineation of CM is not generally
agreed upon, but we have, in line with others, cho-
sen not to include collagen myopathies, as they typ-
ically have a progressive course and more
contractures than other CMs. On follow-up, the
widespread contractures in the 3 collagen VI pa-
tients led to the identification of mutations in the
Figure 2 Detailed muscle strength and vital capacity in various genetic subtypes of congenital myopathy
For Medical Research Council (MRC); gray bars left side, black bars right side. Bottom: forced vital capacity (FVC) in percentage of expected normal values.
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collagen VI genes, and in the patients with desmin
mutations, the course showed to be much more
progressive than was the impression at the initial
visit. Hence, in retrospect, the collagen VI myopa-
thies and the desmin patients should not have been
included. By contrast, there were no red flags in the
phenotype of the collagen XII patients and the pa-
tients with CMSs. The prevalence would not have
been significantly different if these patients were
included, as the total patient number compared
to the complete population is still very small.
In contrast to most previous studies, we included
many adult patients with very early-onset weakness.
We confirmed that for the majority, the disease
course is nonprogressive and many patients are still
engaged in an active work life.
Taken together, this study adds new knowledge
about the geographic variation in prevalence, dis-
tribution of subtypes, and clinical characteristics
in an older population with CM that may influ-
ence strategies for diagnostic testing and counsel-
ing of patients.
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